Call for proposals to support the development of a medicine pricing, reimbursement and access tracker through the EURIPID database

Expected Impact

In the short term, this action will provide EURIPID members with a better overview of access, P&R measures and decisions across the Member States.

In the longer term, it is expected to support mutual learning between national authorities and help the Member States in taking better pricing and reimbursement decisions, with a view to improve access, availability, and affordability of medicines. This is in line with the recommendations in the Draghi Report on the future of European competitiveness, and with the priority to ensure supply of affordable medicines, as outlined in the mission letter from Commission President von der Leyen to the Commissioner for Health and Animal Welfare.

The proposed “pricing and reimbursement (‘P&R’) tracker” and access dashboard will allow improved monitoring of patients’ access to medicines across the Union, including for cancer treatments. Having this data available prior to the application of the proposed pharmaceutical reform, will serve to measure the baseline and subsequently the impact of the proposed measures that aim to increase access to medicines across the Union, including for cancer treatments.

Objective

The objectives are to:

a) measure and increase understanding of patient access to medicines in the Union;

b) increase the quality of the database, in terms of timely/correct data delivery;

c) expand the scope of the EURIPID members (to all the Member States) and data;

d) leverage usefulness of the data beyond external reference pricing purposes.

Scope

The scope of this action is to develop through the EURIPID database:

a) a “pricing and reimbursement (‘P&R’) tracker”, including national information on early access schemes; P&R applications, status, decision; and P&R criteria or conditions (general and product-specific);

b) access dashboards, building on OECD indicators, including on availability (e.g., coverage status, time-to-reimbursement), affordability (e.g., cost of treatment), accessibility (e.g., consumption/uptake);

c) an annual trend analysis report of access to medicines in the Union;

d) solutions that can facilitate data sharing with EURIPID, such as automatization using application programming interface and machine-machine interaction with each Member State;

e) reinforced interoperability of EURIPID with other existing databases (e.g. the European Shortages Medicine Platform, Substance, Product, Organisation and Referential master data, Product Management Service, etc.) and integrating data assets in the European Health Data Space.